entertainment -WSS

entertainment

author：knowledge 2025-09-02 09:55:59 - browse：33773

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： The untold story of TV’s first prescription drug ad

knowledge

hotspot

WSS

Pancreatic cancer is often deadly, but new discoveries are raising hope

Longer MASH drug regimen improved liver, Akero study finds

Study: Black kids more likely to die after surgery than white kids

Four alarming medical procedures we’re glad history forgot

Medicare drug price negotiation hearing pits pharma v Biden admin

Drug companies' payments and gifts affect physicians' prescribing

explore

entertainment

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Streamlined flu vaccines recommended by FDA advisory panel

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Walensky prepares to leave CDC — and Congress — behind

Young boy dies in trial for Pfizer Duchenne gene therapy

What does generative AI mean for health care? We asked experts

Multiple sclerosis has subtypes with different best treatments: study

Hepatitis C has a cure — but many Americans still lack access to it

He's 19 months old and has one of the world’s rarest diseases

focus

Families look for replacement for GSK asthma drug Flovent

Change Healthcare: What is it, why does its cyberattack matter?

Trial using CRISPR to edit HIV out of cells disappoints

U.K. decision on ALS drug has neurologists, advocates up in arms

Florida health officials providing scant details on measles cases

He's 19 months old and has one of the world’s rarest diseases

knowledge

hotspot

focus

explore